vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $13.3M, roughly 1.4× OCULAR THERAPEUTIX, INC). CuriosityStream Inc. runs the higher net margin — -19.7% vs -488.0%, a 468.2% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -22.4%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-57.1M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -5.3%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

CURI vs OCUL — Head-to-Head

Bigger by revenue
CURI
CURI
1.4× larger
CURI
$19.2M
$13.3M
OCUL
Growing faster (revenue YoY)
CURI
CURI
+58.3% gap
CURI
35.8%
-22.4%
OCUL
Higher net margin
CURI
CURI
468.2% more per $
CURI
-19.7%
-488.0%
OCUL
More free cash flow
CURI
CURI
$61.0M more FCF
CURI
$3.9M
$-57.1M
OCUL
Faster 2-yr revenue CAGR
CURI
CURI
Annualised
CURI
26.5%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
OCUL
OCUL
Revenue
$19.2M
$13.3M
Net Profit
$-3.8M
$-64.7M
Gross Margin
88.0%
Operating Margin
-17.6%
-526.5%
Net Margin
-19.7%
-488.0%
Revenue YoY
35.8%
-22.4%
Net Profit YoY
-34.6%
-33.6%
EPS (diluted)
$-0.07
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
OCUL
OCUL
Q4 25
$19.2M
$13.3M
Q3 25
$18.4M
$14.5M
Q2 25
$19.0M
$13.5M
Q1 25
$15.1M
$10.7M
Q4 24
$14.1M
$17.1M
Q3 24
$12.6M
$15.4M
Q2 24
$12.4M
$16.4M
Q1 24
$12.0M
$14.8M
Net Profit
CURI
CURI
OCUL
OCUL
Q4 25
$-3.8M
$-64.7M
Q3 25
$-3.7M
$-69.4M
Q2 25
$784.0K
$-67.8M
Q1 25
$319.0K
$-64.1M
Q4 24
$-2.8M
$-48.4M
Q3 24
$-3.1M
$-36.5M
Q2 24
$-2.0M
$-43.8M
Q1 24
$-5.0M
$-64.8M
Gross Margin
CURI
CURI
OCUL
OCUL
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
Operating Margin
CURI
CURI
OCUL
OCUL
Q4 25
-17.6%
-526.5%
Q3 25
-24.5%
-472.3%
Q2 25
2.5%
-502.6%
Q1 25
0.5%
-597.5%
Q4 24
-27.4%
-296.1%
Q3 24
-25.8%
-298.2%
Q2 24
-20.6%
-265.1%
Q1 24
-30.4%
-214.0%
Net Margin
CURI
CURI
OCUL
OCUL
Q4 25
-19.7%
-488.0%
Q3 25
-20.4%
-477.3%
Q2 25
4.1%
-503.9%
Q1 25
2.1%
-598.7%
Q4 24
-19.9%
-283.3%
Q3 24
-24.3%
-236.6%
Q2 24
-16.4%
-266.3%
Q1 24
-42.0%
-438.9%
EPS (diluted)
CURI
CURI
OCUL
OCUL
Q4 25
$-0.07
$-0.27
Q3 25
$-0.06
$-0.38
Q2 25
$0.01
$-0.39
Q1 25
$0.01
$-0.38
Q4 24
$-0.05
$-0.25
Q3 24
$-0.06
$-0.22
Q2 24
$-0.04
$-0.26
Q1 24
$-0.09
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$27.3M
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$654.3M
Total Assets
$75.7M
$808.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
OCUL
OCUL
Q4 25
$27.3M
$737.1M
Q3 25
$27.8M
$344.8M
Q2 25
$28.1M
$391.1M
Q1 25
$33.4M
$349.7M
Q4 24
$32.1M
$392.1M
Q3 24
$33.2M
$427.2M
Q2 24
$39.5M
$459.7M
Q1 24
$38.8M
$482.9M
Stockholders' Equity
CURI
CURI
OCUL
OCUL
Q4 25
$41.5M
$654.3M
Q3 25
$47.2M
$258.2M
Q2 25
$49.8M
$305.9M
Q1 25
$58.1M
$265.9M
Q4 24
$57.8M
$315.3M
Q3 24
$62.2M
$352.0M
Q2 24
$64.8M
$377.7M
Q1 24
$67.0M
$408.0M
Total Assets
CURI
CURI
OCUL
OCUL
Q4 25
$75.7M
$808.1M
Q3 25
$74.7M
$410.9M
Q2 25
$78.7M
$451.3M
Q1 25
$85.3M
$405.9M
Q4 24
$86.2M
$457.9M
Q3 24
$87.6M
$490.4M
Q2 24
$90.9M
$517.1M
Q1 24
$94.6M
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
OCUL
OCUL
Operating Cash FlowLast quarter
$4.0M
$-54.2M
Free Cash FlowOCF − Capex
$3.9M
$-57.1M
FCF MarginFCF / Revenue
20.5%
-430.9%
Capex IntensityCapex / Revenue
0.1%
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
OCUL
OCUL
Q4 25
$4.0M
$-54.2M
Q3 25
$4.4M
$-50.7M
Q2 25
$2.8M
$-55.2M
Q1 25
$1.9M
$-44.7M
Q4 24
$3.0M
$-39.4M
Q3 24
$2.3M
$-36.6M
Q2 24
$2.2M
$-24.8M
Q1 24
$666.0K
$-33.9M
Free Cash Flow
CURI
CURI
OCUL
OCUL
Q4 25
$3.9M
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$1.8M
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
CURI
CURI
OCUL
OCUL
Q4 25
20.5%
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
12.2%
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
CURI
CURI
OCUL
OCUL
Q4 25
0.1%
21.4%
Q3 25
0.0%
41.2%
Q2 25
0.0%
9.3%
Q1 25
0.5%
18.1%
Q4 24
0.0%
1.2%
Q3 24
0.0%
0.6%
Q2 24
0.0%
4.5%
Q1 24
0.0%
1.7%
Cash Conversion
CURI
CURI
OCUL
OCUL
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons